earticle

영어

BACKGROUND Many antipsychotic drugs have been used to treat schizophrenia, and many treatment patterns have been observed. Most schizophrenia treatment pattern studies were done by analyzing survey data or several hospitals’ electronic health records. This study aimed to analyze early treatment pathways of newly diagnosed schizophrenia patients. METHOD Using 2012-2017 Health Insurance Review & Assessment Service-National Patients Sample (HIRA-NPS) which was standardized to the Common Data Model (CDM), we selected newly diagnosed schizophrenia patients. The inclusion criteria were 18-64 aged patients who have continuous observation at least 30 days before and 180 days after index date, and patients who have at least one diagnosis of schizophrenia between pre-index date and 180 days after index date. The exclusion criterion was patients who have diagnosis of bipolar disorder or depressive disorder. We used Observational Health Data Sciences and Informatic (OHDSI)’s ATLAS platform to analyze baseline characteristics and treatment patterns of selected patients. RESULTS For the schizophrenia first line treatment, risperidone was the most commonly used treatment in all years (2012-2017), followed by aripiprazole and olanzapine. Among typical antipsychotics, haloperidol was the most commonly used treatment. The patients with younger age were more likely to use second or later line drugs. CONCLUSIONS We comprehensively evaluated the treatment pathway of antipsychotics in adult patients with schizophrenia by using representative claims data that was standardized to the CDM. This study found the most commonly used antipsychotics by different age groups and the proportion of patients who switched to later line treatments.